Collaboration term for current and future clinical programs.

No definition available.

Name:	rcus_CollaborationTermForCurrentAndFutureClinicalPrograms
Namespace Prefix:	rcus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Board Members

+ References

No definition available.

+ Details

Name:	rcus_NumberOfBoardMembers
Namespace Prefix:	rcus_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of exercise option to programs.

+ References

No definition available.

+ Details

Name:	rcus_NumberOfExerciseOptionToPrograms
Namespace Prefix:	rcus_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of programs, eligible to receive regulatory and commercial milestone payments.

+ References

No definition available.

+ Details

Name:	rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments
Namespace Prefix:	rcus_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of research programs.

+ References

No definition available.

+ Details

Name:	rcus_NumberOfResearchPrograms
Namespace Prefix:	rcus_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Option continuation payment due upon Eighth anniversary of agreement.

+ References

No definition available.

+ Details

Name:	rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Option continuation payment due upon Fourth anniversary of agreement.

+ References

No definition available.

+ Details

Name:	rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Option continuation payment due upon second anniversary of agreement.

+ References

No definition available.

+ Details

Name:	rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Option continuation payment due upon Sixth anniversary of agreement.

+ References

No definition available.

+ Details

Name:	rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Option fee per program for all other programs entering clinical development to exercise option.

+ References

No definition available.

+ Details

Name:	rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Option payment received.

+ References

No definition available.

+ Details

Name:	rcus_OptionPaymentReceived
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Option payment upon achievement of certain development milestones.

+ References

No definition available.

+ Details

Name:	rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Option payment upon completion of certain IND-enabling activities.

+ References

No definition available.

+ Details

Name:	rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of outstanding common stock owned.

+ References

No definition available.

+ Details

Name:	rcus_PercentageOfOutstandingCommonStockOwned
Namespace Prefix:	rcus_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Potential regulatory approval milestones payment receivable related to domvanalimab.

+ References

No definition available.

+ Details

Name:	rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Regulatory and commercial milestone payments received.

+ References

No definition available.

+ Details

Name:	rcus_RegulatoryAndCommercialMilestonePaymentsReceived
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Related party transaction reimbursement from related party for shared costs.

+ References

No definition available.

+ Details

Name:	rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Remove option continuation payment under agreement.

+ References

No definition available.

+ Details

Name:	rcus_RemoveOptionContinuationPaymentUnderAgreement
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Sale Of Stock, Number Of Shares Acquired In Transaction

+ References

No definition available.

+ Details

Name:	rcus_SaleOfStockNumberOfSharesAcquiredInTransaction
Namespace Prefix:	rcus_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Total Upfront Cash Payment

+ References

No definition available.

+ Details

Name:	rcus_TotalUpfrontCashPayment
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront cash payment.

+ References

No definition available.

+ Details

Name:	rcus_UpfrontCashPayment
Namespace Prefix:	rcus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

+ Details

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rcus_GileadSciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=rcus_CommonStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party - Gilead Sciences, Inc. (Details) shares in Millions, $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2026 USD ($) program member	Mar. 31, 2025 USD ($) shares	Dec. 31, 2023 USD ($) program	Dec. 31, 2021 USD ($) program	Dec. 31, 2020 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Related Party Transaction [Line Items]
Sale of stock, consideration received on transaction		$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments \| program			4
Revenue recognized from amounts in deferred revenue at the beginning of the period	$ 17.0	28.0
Accounts payable, current	$ 39.0					$ 42.0
Gilead
Related Party Transaction [Line Items]
Sale of stock, consideration received on transaction		$ 15.0
Gilead
Related Party Transaction [Line Items]
Sale of stock, number of shares acquired in transaction (in shares) \| shares		1.4
Related Party
Related Party Transaction [Line Items]
Percentage of outstanding common stock held	25.00%
Accounts payable, current	$ 11.0					$ 24.0
Related Party \| Research and Development
Related Party Transaction [Line Items]
Reimbursement from related party for shared costs		$ (5.0)
Purchase Agreement \| Related Party
Related Party Transaction [Line Items]
Number of board members \| member	3
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Option payment upon completion of certain IND-enabling activities	$ 60.0
Option payment upon achievement of certain development milestones	$ 150.0
Gilead Collaboration Agreement \| Related Party
Related Party Transaction [Line Items]
Collaboration term for current and future clinical programs					10 years
Option continuation payment due upon second anniversary of agreement					$ 100.0
Option continuation payment due upon fourth anniversary of agreement					100.0		$ 100.0
Option continuation payment due upon sixth anniversary of agreement					100.0
Option continuation payment due upon eighth anniversary of agreement					100.0
Upfront cash payment					$ 175.0
Option fee per program for all other programs entering clinical development to exercise option				$ 150.0
Number of research programs \| program	2
Revenue recognized from amounts in deferred revenue at the beginning of the period	$ 15.0	$ 28.0
Gilead Collaboration Agreement \| Related Party \| Maximum
Related Party Transaction [Line Items]
Potential regulatory approval milestones payment receivable related to domvanalimab				$ 500.0
Amended Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Number of exercise option to programs \| program				3
Option payments received				$ 725.0
Removal of option continuation payment under agreement				$ 100.0
Option payment upon achievement of certain development milestones			$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments \| program			2
Amended Gilead Collaboration Agreement \| Related Party
Related Party Transaction [Line Items]
Upfront cash payment			$ 17.5
Number of research programs \| program			2
Option payment upon completion of certain IND-enabling activities			$ 45.0
Total upfront cash payment			35.0
Amended Gilead Collaboration Agreement \| Related Party \| Maximum
Related Party Transaction [Line Items]
Regulatory and commercial milestone payments received			$ 375.0